<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05118776</url>
  </required_header>
  <id_info>
    <org_study_id>ASC40-301</org_study_id>
    <nct_id>NCT05118776</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM</brief_title>
  <official_title>A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate Safety and Efficacy pf ASC40 Tablets Combined With Bevacizumab in Subjects With Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascletis Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascletis Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, controlled and multi-center Phase III clinical trial to&#xD;
      evaluate the safety and efficacy of ASC40 tablets combined with bevacizumab in the treatment&#xD;
      of adult patients with recurrent glioblastoma. After standard radiotherapy and chemotherapy&#xD;
      (temozolomide), the subject first experienced clinical recurrence or progression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 18, 2021</start_date>
  <completion_date type="Anticipated">September 16, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 16, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months</time_frame>
    <description>The time of progression or death from any cause in randomly grouped diseases (whichever comes first) was compared with the control group (evaluated by Independent Imaging Evaluation Committee [IRC])</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 10 months</time_frame>
    <description>the time from random grouping to death, compared with the control group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective remission rate</measure>
    <time_frame>Week 4 to Month 6 (every 8 weeks)</time_frame>
    <description>It is evaluated once in the 4th week after using experimental drugs (experimental drug group or control group), and then every 8 weeks until the disease progresses or dies (evaluated by [IRC]).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Recurrent Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Team ASC40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASC40 tablets 100mg/m^2 and bevacizumab 10mg/kg for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Team Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and bevacizumab 10mg/kg for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASC40 tablets</intervention_name>
    <description>ASC40 were taken orally once a day for 6 months.</description>
    <arm_group_label>Team ASC40</arm_group_label>
    <other_name>TVB-2640</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablets</intervention_name>
    <description>Placebo were taken orally once a day for 6 months.</description>
    <arm_group_label>Team Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab once every 2 weeks, intravenous drip, for 6 months.</description>
    <arm_group_label>Team ASC40</arm_group_label>
    <arm_group_label>Team Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Age â‰¥18 years old, both male and female;&#xD;
&#xD;
          -  2. Histologically confirmed glioblastoma;&#xD;
&#xD;
          -  3. Patients with glioblastoma who have failed standard treatment (surgery, Stupp&#xD;
             regimen), were diagnosed by MRI and evaluated by RANO standard to support the first&#xD;
             recurrence. Stupp regimen needs to complete at least 6 medication cycles.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Use low molecular weight heparin and warfarin within 35 days before randomization;&#xD;
&#xD;
          -  2. Arterial or venous thrombosis (such as cerebral infarction, myocardial infarction,&#xD;
             venous thrombosis of lower limbs, arterial embolism of lower limbs, pulmonary&#xD;
             embolism, etc.) occurred within 6 months before randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wenbin Li, Doctor</last_name>
    <phone>86-010-59975034</phone>
    <email>neure55@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhuang Kang, Master</last_name>
    <phone>86-010-59975034</phone>
    <email>kzhaoren1984@163.com</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASC40</keyword>
  <keyword>Recurrent Glioblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

